gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Anaplastic lymphoma receptor tyrosine kinase

ALK, anaplastic lymphoma kinase
This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011] (from NCBI)
Top mentioned proteins: EGFR, HAD, CAN, EML4, Ros
Papers using ALK antibodies
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
Gaits-Iacovoni F et al., In Blood Cancer Journal, 2009
... The following antibodies were used in this study: ALK (Sp8; Abcam, Cambridge, UK), B220/CD45R (RA3-6B2; ...
Low-affinity nerve growth factor receptor p75NTR immunoreactivity in the myocardium with sympathetic hyperinnervation
Twigg Stephen M. et al., In Journal of Cell Communication and Signaling, 2003
... Pan anti-TGF-β neutralizing antibody was purchased from R&D systems Inc (Minneapolis, USA) and Alk 5 inhibitor (SB 431542) was purchased from Tocris Cookson Inc, Ellisville, Missouri ...
Alternative splicing and hypermutation of a nonproductively rearranged TCR α-chain in a T cell hybridoma
Küppers Ralf et al., In The Journal of Experimental Medicine, 1998
... A), CD20, LMP1, anaplastic lymphoma kinase (ALK)-1 (Dako), CD15 ( ...
Follicular dendritic cell tumor of the liver. Evidence for an Epstein-Barr virus-related clonal proliferation of follicular dendritic cells
Vasef Mohammad A. et al., In Journal of Hematopathology, 1995
... The following antibodies were used: CD3, CD5, CD15, CD23, CD34, ALK protein (Ventana Medical Systems, Tucson, AZ, USA); smooth ...
Skeletal complications in hairy cell leukemia: diagnosis and therapy
Sohani Aliyah R. et al., In Journal of Hematopathology, 1987
Papers on ALK
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
Chang et al., Seoul, South Korea. In Cancer Biol Ther, Feb 2016
Among the 115 missense mutations discovered in the tested genes, a few number of actionable mutations were detected irrelevant to the subtype of EGFR mutations, including ALK rearrangement, BCL2L11 intron 2 deletion, KRAS c.35G>A, PIK3CA c.1633G>A which are possible target of crizotinib, BH3 mimetics, MEK inhibitors, and PI3K-tyrosine kinase inhibitors, respectively.
Advances in the Clinicopathologic and Molecular Classification of Cutaneous Mesenchymal Neoplasms.
Doyle et al., Dublin, Ireland. In Histopathology, Feb 2016
Genetic characterization of several soft tissue tumour types that occur in the skin has resulted in the identification of diagnostically useful markers: ALK gene rearrangement with corresponding ALK protein expression by immunohistochemistry in epithelioid fibrous histiocytoma; WWTR1-CAMTA1 fusion gene with CAMTA1 protein expression in epithelioid haemangioendothelioma; MYC amplification and overexpression in radiation-associated angiosarcoma; and EWSR1 gene rearrangement in cutaneous myoepithelial tumours.
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Richards et al., Seoul, South Korea. In Cell Mol Life Sci, Feb 2016
UNASSIGNED: A fusion between the EML4 (echinoderm microtubule-associated protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit of patients.
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Contessa et al., New Haven, United States. In J Clin Oncol, Feb 2016
PURPOSE: We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and brain metastasis.
Primary hepatic Epstein-Barr virus-associated CD30-positive peripheral T-cell lymphoma of cytotoxic phenotype.
Qing et al., Torrance, United States. In Exp Mol Pathol, Feb 2016
By immunohistochemistry, the lymphoma cells expressed CD2, CD3, CD8, CD30, CD43, CD45, granzyme B, TIA-1, and negative for CD4, CD5, CD7, CD56, βF1, ALK-1, and B-cell markers.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Engelman et al., Tokyo, Japan. In N Engl J Med, Feb 2016
In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain.
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
Planchard et al., Villejuif, France. In Ther Adv Med Oncol, Jan 2016
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small molecule inhibitor of ALK, ROS1 and MET.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
study investigators et al., Boston, United States. In Lancet Oncol, Jan 2016
BACKGROUND: Alectinib-a highly selective, CNS-active, ALK inhibitor-showed promising clinical activity in crizotinib-naive and crizotinib-resistant patients with ALK-rearranged (ALK-positive) non-small-cell lung cancer (NSCLC).
Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Ying et al., Beijing, China. In Oncotarget, Jan 2016
UNASSIGNED: To investigate the use of molecular testing on cytological specimens in selecting advanced non-small cell lung cancer (NSCLC) patients who are adequate for targeted treatment, a total of 137 NSCLC cases were analyzed by fluorescence in situ hybridization (FISH) for anaplastic lymphoma kinase (ALK) rearrangements, and Epidermal growth factor receptor (EGFR), kirsten rat sarcoma viral oncogene homolog (KRAS) mutations were evaluated by quantitative real-time PCR (qRT-PCR) platform combining amplification refractory mutation system (ARMS) primers and TaqMan probes.
Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Portier et al., Houston, United States. In Adv Exp Med Biol, Dec 2015
The two clinically validated and Food and Drug Administration approved lung cancer predictive biomarkers (epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) translocations) occur in only about 20 % of lung adenocarcinomas and acquired resistance develops to first generation drugs.
EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer.
Zhang et al., Zhengzhou, China. In Oncol Lett, Dec 2015
UNASSIGNED: Non-small-cell lung cancer (NSCLC) with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation is resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, but responds to the ALK-TKI crizotinib.
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Yang et al., Beijing, China. In Sci Rep, Dec 2015
ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
Kim et al., Orange, United States. In J Clin Oncol, Dec 2015
PURPOSE: Crizotinib confers improved progression-free survival compared with chemotherapy in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), but progression invariably occurs.
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.
Chi et al., New York City, United States. In Nature, Nov 2015
Here we report a novel isoform of the anaplastic lymphoma kinase (ALK) that is expressed in ∼11% of melanomas and sporadically in other human cancer types, but not in normal tissues.
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells.
Schatz et al., Miami, United States. In Biomark Cancer, 2014
This is highlighted in particular by recent studies of mutant-BRAF in melanoma and the fusion kinase nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) in anaplastic large cell lymphoma.
Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
Gong et al., Beijing, China. In Leuk Res, 2012
Extra copies of ALK gene locus are a frequent genetic aberration in both ALK-positive and ALK-negative anaplastic large cell lymphomas and is a favorable prognostic marker for the patients.
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
George et al., United Kingdom. In Cancer Cell, 2012
findings demonstrate a pathogenic role for ALK(F1174L) in neuroblastomas overexpressing MYCN and suggest a strategy for improving targeted therapy for ALK-positive neuroblastoma
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer.
Comb et al., Danvers, United States. In Cancer Res, 2012
immunohistochemical analysis of ovarian tumor tissue microarray detected aberrant ALK expression in 2% to 4% serous carcinoma patients
ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
Bell et al., Rochester, United States. In Arch Pathol Lab Med, 2012
This is the first report, to our knowledge, of ALK gene rearrangements in inflammatory myofibroblastic tumors in the female genital tract.
Anaplastic lymphoma kinase in human cancer.
Palmer et al., Umeå, Sweden. In Crit Rev Oncog, 2011
review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment
share on facebooktweetadd +1mail to friends